Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery. [PDF]
Bello W +8 more
europepmc +1 more source
HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES. [PDF]
Vempuluru VS, Raval V, Kaliki S.
europepmc +1 more source
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer. [PDF]
Liu Y +15 more
europepmc +1 more source
Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]
Khan SM +3 more
europepmc +1 more source
Comment on: Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]
Rani T, Mandal R, Bandyopadhyay A.
europepmc +1 more source
Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies. [PDF]
Shunyakov L +5 more
europepmc +1 more source
High-Risk neuroblastoma therapeutics Topotecan and 13-cis-Retinoic acid modulate autophagy and induce DNA damage response in hematopoietic stem cells and monocytes. [PDF]
Lázničková P +5 more
europepmc +1 more source
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma. [PDF]
Han JZR +19 more
europepmc +1 more source
Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. [PDF]
Liu Y, Xu M, Ma J, Zhu Y, Gao M.
europepmc +1 more source
Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. [PDF]
Zheng H, Wen F, Wu B.
europepmc +1 more source

